SOLVD Health’s Pharmacogenomics Test Receives New York State Department of Health Approval

SAN DIEGO–(BUSINESS WIRE)–SOLVD Health, a patient intelligence company pioneering precision medicine through advanced genetics and AI-driven insights, announced today that its pharmacogenomics (PGx) test PreScript has received approval from the New York State Department of Health’s Clinical Laboratory Evaluation Program (CLEP). This milestone enables SOLVD Health to offer its PGx testing services to healthcare providers and patients across New York State, one of the most rigorously regulated laboratory markets in the nation.

Pharmacogenomic testing plays a critical role in precision medicine, helping clinicians tailor drug therapies based on an individual’s genetic profile. By identifying genetic variations that influence drug metabolism and response, PGx testing empowers providers to optimize treatment plans, reduce adverse drug reactions, and improve patient outcomes.

“Approval from the New York State Department of Health underscores our commitment to delivering actionable insights that transform healthcare,” said Dr. Keri Donaldson, Founder and President of SOLVD Health. “Pharmacogenomics is a cornerstone of personalized medicine, and this clearance allows us to expand access to tools that help clinicians make safer, more effective prescribing decisions.”

This achievement builds on SOLVD Health’s proven track record of innovation, including its FDA-approved AvertD® test, the first genetic test designed to assess elevated risk for opioid use disorder prior to prescribing oral opioids. Leveraging AI-powered analytics and proprietary algorithms, SOLVD Health continues to advance its mission of preventing disease and improving health outcomes through predictive, personalized insights.

About SOLVD Health

SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about SOLVD Health, visit www.solvdhealth.com.

Contacts

SOLVD Health
Mark Hazeltine

[e-mail]

Media Contact
Katie Kennedy

Gregory

[e-mail]